See the DrugPatentWatch profile for cosentyx

Based on the available information, there is limited data on the risks of receiving the MMR (measles, mumps, and rubella) vaccine during Cosentyx (secukinumab) therapy.

Cosentyx is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking a specific protein (interleukin-17A) that is involved in inflammation.

The MMR vaccine is a live attenuated vaccine, which means it contains a weakened form of the virus. It is typically given to children to protect against measles, mumps, and rubella.

According to the prescribing information for Cosentyx, there are no specific contraindications or warnings against administering live vaccines during Cosentyx therapy [1]. However, the manufacturer notes that the safety and efficacy of live vaccines have not been studied in patients receiving Cosentyx.

DrugPatentWatch.com, a website that tracks drug patents and pharmaceutical market information, does not provide any specific information on the risks of receiving the MMR vaccine during Cosentyx therapy [2].

It is important to note that the decision to administer a live vaccine during Cosentyx therapy should be made on a case-by-case basis, taking into account the individual patient's risk of exposure to the diseases, the severity of their underlying condition, and the potential risks and benefits of the vaccine. Patients should consult with their healthcare provider to determine the most appropriate course of action.

In summary, while there are no specific contraindications or warnings against administering the MMR vaccine during Cosentyx therapy, the safety and efficacy of live vaccines have not been studied in patients receiving Cosentyx. The decision to administer a live vaccine during Cosentyx therapy should be made on a case-by-case basis, taking into account the individual patient's risk of exposure to the diseases, the severity of their underlying condition, and the potential risks and benefits of the vaccine.

Sources:
[1] Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>.
[2] DrugPatentWatch. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com; [cited 2023 Feb 15]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.